- Home >
- Life Sciences >
- Pharmaceutical >
MarketWatch: Health Round-up
MarketWatch: Health Round-up
- Report price : $ 400
- Publication date : January 2009
- Length : 42 pages
MarketWatch: Health Round-up
Datamonitor's MarketWatch Health Round-up is a one-stop news shop for time-pressed executives. It provides monthly insight into the key events in the Healthcare industry. The report contains the latest news, analysis and opinion, covering all the month's major issues and events in R&D, regulatory and licensing in the Healthcare industry.
RELATED REPORTS
MarketWatch: CNS
- $ 200
- January 2009
- 23 pages
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives. It provides monthly insight into the key events in the CNS industry. The report contains the latest news, analysis and opinion, covering all the month's major issues and events in R&D, regulatory and licensing in theCN ...
Industries : Pharmaceutical
MarketWatch: Cancer
- $ 200
- January 2009
- 31 pages
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives. It provides monthly insight into the key events in the cancer therapeutic area. MarketWatch features all the major current business issues and events, including R&D news, licensing deals, alliances and joint ventu ...
Industries : Pharmaceutical
Delivery Mechanisms for Large Molecule Drugs: Successes and failures of leading technologies and key drivers for market success
- $ 3 835
- January 2009
- 138 pages
Delivery Mechanisms for Large Molecule DrugsSuccesses and failures of leading technologies and key drivers for market successEmerging drug delivery technologies aim to improve measures of safety, efficacy, convenience and compliance in both new and existing drug candidates and products. For currentl ...
Industries : Pharmaceutical
The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis
- $ 3 835
- January 2009
- 197 pages
The Cardiovascular Market Outlook to 2013The cardiovascular therapy area spans a range of treatment classes including anti-hypertensives, anti-dyslipidemics, anti-thrombotics, hematological preparations and cardiac therapies. Each sub-therapy area is facing a different set of issues and challenges, ...
Industries : Pharmaceutical
Abdominal Aortic Aneurysm Pipeline Product and Technology Analysis Report
- $ 2 000
- December 2008
- 29 pages
Abdominal Aortic Aneurysm Pipeline Product and Technology Analysis ReportSummaryGlobal Markets Direct's “Pipeline Products and Technology Analysis Report” is an essential source of information and analysis on pipeline medical devices, which are expected to bring significant shift to the prevalen ...
Industries : Pharmaceutical
Forecast Insight: Antithrombotics - Market growth dependent on new agents
- $ 15 200
- December 2008
- 73 pages
IntroductionThe antithrombotic market is expected to grow to $22 billion by 2017. The growth will mainly be due to the introduction of new agents onto the market, such as prasugrel and rivaroxaban, which will offer significant improvements over the current standards of care (Plavix (clopidogrel) and ...
Industries : Pharmaceutical
Forecast Insight: Epilepsy - Future market upgrade following new drug launches
- $ 15 200
- December 2008
- 140 pages
IntroductionDriven primarily by continued uptake of UCB's market leading anticonvulsant, Keppra (levetiracetam), seven major market epilepsy revenues grew strongly at a compound annual growth rate of 11.7% to reach almost $3.8 billion in 2007.Scope*This report gives a strategic analysis of the likel ...
Industries : Pharmaceutical
Pharmaceutical Company Outlook to 2013
- $ 7 600
- December 2008
- 137 pages
IntroductionPharmaVitae universe Rx sales are forecast to expand at a 2007-13 CAGR of 2.4%, down 7.6 percentage points from 2001-07. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a sh ...
Industries : Pharmaceutical
Divestment Strategies: Pharma is divesting in order to grow
- $ 3 800
- December 2008
- 68 pages
IntroductionPharmaceutical companies are now divesting non-core assets such as medical devices and manufacturing plants in an effort to cut costs and focus on core strategies, primarily drug development. However, while some Pharma companies are narrowing their focus, targeting specific disease areas ...
Industries : Pharmaceutical
Stakeholder Opinions: Sarcomas
- $ 3 800
- December 2008
- 108 pages
IntroductionSarcomas are a diverse group of rare connective tissue tumors that are categorized as soft tissue sarcomas or bone sarcomas. Although sarcomas represent only 1% of all adult and 15% of all childhood cancers, the development of metastatic disease is a major clinical problem as cure is le ...
Industries : Pharmaceutical
Related industries
reportlinker.com © Copyright 2009. All rights reserved